Dr. Charles D. Lopez
Claim this profileOHSU Knight Cancer Institute
Studies Pancreatic Cancer
Studies Stomach Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
BRCA1 positive
2Stomach Cancer
Stage IV
Stage III
BRCA1 positive
Affiliated Hospitals
Clinical Trials Charles D. Lopez is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Calaspargase + Cobimetinib
for Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of calaspargase pegol-mknl in combination with cobimetinib in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Cobimetinib attacks a protein called MEK that has been known to stimulate cells that promote the growth of cancer cells in the body. Calaspargase pegol-mknl is an enzyme that converts the amino acid L-asparagine into aspartic acid and ammonia. Many types of cancer cell rely on the amino acid L-asparagine, and depleting this amino acid with calaspargase pegol-mknl starves cancer cells of this nutrient. Attacking the MEK protein with cobimetinib is thought to further prevent cancer cells from using this amino acid, causing them to die. Giving calaspargase pegol-mknl in combination with cobimetinib may help control the disease in patients with pancreatic cancer.
Recruiting1 award Phase 117 criteria
More about Charles D. Lopez
Clinical Trial Related3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Charles D. Lopez has experience with
- Cobimetinib
- Olaparib
- Onvansertib
- Nab-paclitaxel
- Fluorouracil
- Irinotecan Hydrochloride
Breakdown of trials Charles D. Lopez has run
Pancreatic Cancer
Stomach Cancer
Pancreatic Adenocarcinoma
Pancreatic intraepithelial neoplasia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Charles D. Lopez specialize in?
Charles D. Lopez focuses on Pancreatic Cancer and Stomach Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Charles D. Lopez currently recruiting for clinical trials?
Yes, Charles D. Lopez is currently recruiting for 3 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Charles D. Lopez has studied deeply?
Yes, Charles D. Lopez has studied treatments such as Cobimetinib, Olaparib, Onvansertib.
What is the best way to schedule an appointment with Charles D. Lopez?
Apply for one of the trials that Charles D. Lopez is conducting.
What is the office address of Charles D. Lopez?
The office of Charles D. Lopez is located at: OHSU Knight Cancer Institute, Portland, Oregon 97239 United States. This is the address for their practice at the OHSU Knight Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.